Core Viewpoint - The report outlines the ongoing supervisory work conducted by Western Securities for Chongqing Mountain Outside Blood Purification Technology Co., Ltd. (Mountain Outside), emphasizing compliance with regulations and the company's operational status post-IPO [1][2]. Group 1: Supervisory Work - The sponsor has established and effectively implemented a continuous supervision work system, creating specific work plans for ongoing oversight [1]. - A continuous supervision agreement was signed between the sponsor and Mountain Outside, clarifying the rights and obligations of both parties during the supervision period [1]. - The sponsor conducts regular communication, visits, and on-site inspections to understand Mountain Outside's business situation [1][2]. Group 2: Financial Performance - For the first half of 2025, the company reported operating income of CNY 357.25 million, a year-on-year increase of 28.72% [14]. - The total profit reached CNY 60.14 million, reflecting a growth of 34.55% compared to the previous year [14]. - The net profit attributable to shareholders was CNY 55.04 million, marking a 20.28% increase year-on-year [14]. Group 3: Research and Development - The company increased its R&D investment by 37.12% in the first half of 2025, totaling CNY 36.51 million, which represents 10.22% of its operating income [24][25]. - The R&D team expanded to 236 personnel, a growth of 38.01% compared to the previous year [24]. - The company has obtained various patents and certifications, including 62 invention patents and CE certifications for several products, enhancing its competitive edge in the market [19][25]. Group 4: Market Position and Competition - Mountain Outside is positioned as a leading domestic manufacturer of blood purification equipment, benefiting from technological advantages and brand recognition [14][16]. - The company faces competition from established international brands, necessitating continuous innovation and product upgrades to maintain market share [11][12]. - The domestic market for blood purification devices is characterized by intense competition, with imported brands holding significant market shares [11][12]. Group 5: Risk Factors - The company is exposed to various risks, including core competitiveness risks related to technology and talent retention, operational risks associated with regulatory compliance, and financial risks linked to accounts receivable [4][9][10]. - The potential impact of changes in national healthcare policies and market dynamics poses additional challenges to the company's growth and profitability [12][13]. - The company is actively monitoring macroeconomic conditions and trade relations to mitigate risks associated with currency fluctuations and global trade disputes [13].

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，山外山排名 第95位。 最新一期业绩显示，2025年一季报，公司实现营业收入1.89亿元，同比16.77%；净利润3700.64万元， 同比8.10%，销售毛利率46.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13山外山75.7378.693.2355.78亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿1九安医疗11.3611.490.89191.70亿2英科医疗 15.6416.861.39247.04亿3山东药玻16.2816.331.87154.02亿4新华医疗16.6315.411.36106.59亿5奥美医疗 17.1216.781.7661.87亿6振德医疗17.3816.381.1163.10亿7九强生物17.7016.462.1787.65亿8康德莱 18.0418.051.4938.87亿9维力医疗18.5219.782.3343.40亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗 20.2019.812. ...

最新一期业绩显示，2025年一季报，公司实现营业收入1.89亿元，同比16.77%；净利润3700.64万元， 同比8.10%，销售毛利率46.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13山外山74.5977.513.1854.94亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18.2218.241.5139.27亿9奥泰生物18.4419.441.4958.81亿10维力医疗18.4719.732.3243.29亿11鱼跃医疗 20.1919.802.73357.58亿12安图生物20.6219.682.65235.08亿 来源：金融界 截至2025年一季报，共有 ...

Group 1 - The core viewpoint of the news highlights the performance and valuation of Chongqing Mountain Outside Mountain Blood Purification Technology Co., Ltd., indicating a recent stock price increase and a notable PE ratio [1][2] - As of August 11, the company's stock closed at 17.27 yuan, up 4.29%, with a rolling PE ratio of 75.33, marking a new low in 268 days, and a total market capitalization of 5.549 billion yuan [1] - The average PE ratio in the medical device industry is 56.56, with a median of 39.76, positioning the company at 94th in the industry ranking [1][3] Group 2 - The company specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2] - Key products include blood perfusion machines, continuous blood purification devices, and various types of dialysis machines and consumables [2] - The company has received multiple national and provincial awards for its innovations, including the National Science and Technology Progress Award [2] Group 3 - In the latest quarterly report for Q1 2025, the company achieved an operating income of 189 million yuan, representing a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, up 8.10% year-on-year, with a gross profit margin of 46.72% [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Chongqing Shanwaishan Blood Purification Technology Co., Ltd., particularly its stock price, market capitalization, and industry comparisons [1][2]. - As of August 8, the company's stock closed at 16.56 yuan, reflecting a 2.79% increase, with a rolling PE ratio of 72.24, marking a new low in 11 days, and a total market capitalization of 5.321 billion yuan [1]. - The average PE ratio for the medical device industry is 55.70, with a median of 39.08, positioning Shanwaishan at the 93rd rank within the industry [1][3]. Group 2 - Chongqing Shanwaishan specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2]. - The company's main products include blood perfusion machines, continuous blood purification devices, and various types of dialysis machines and consumables [2]. - In the latest quarterly report for Q1 2025, the company reported revenue of 189 million yuan, a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, reflecting a year-on-year growth of 8.10%, with a gross profit margin of 46.72% [2].

8月4日，山外山今日收盘15.94元，上涨2.31%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到69.53倍，总市值51.22亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，山外山排名 第92位。 股东方面，截至2025年3月31日，山外山股东户数7938户，较上次增加979户，户均持股市值35.28万 元，户均持股数量2.76万股。 重庆山外山血液净化技术股份有限公司的主营业务是血液净化设备与耗材的研发、生产和销售，并提供 连锁血液透析医疗服务。公司的主要产品是血液灌流机、连续性血液净化设备、血液透析机、血液净化 设备、血液透析浓缩液、血液透析干粉、血液透析器（低通）、血液透析器（高通）、透析液过滤器、 连续性血液净化管路、一次性使用血液灌流器、连锁血液透析中心医疗服务、智慧血透管理。公司项 目"血液净化系统监测与控制系列关键技术及整机设备"荣获国家科学技术进步二等奖，还先后获得国家 信息产业重大技术发明奖、中国电子信息科学技术发明一等奖、中国仪器仪表科学技术一等奖、中国标 准创新贡献奖、中国专利银奖等多项国家和部级奖励，被国家科技部评为国 ...

Company Overview - Chongqing Shanwaishan Blood Purification Technology Co., Ltd. specializes in the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2] - The main products include blood perfusion machines, continuous blood purification devices, blood dialysis machines, and various blood purification consumables [2] - The company has received multiple national and provincial awards for its technological innovations, including the National Science and Technology Progress Award [2] Financial Performance - For Q1 2025, the company reported a revenue of 189 million yuan, representing a year-on-year increase of 16.77% [2] - The net profit for the same period was approximately 37.01 million yuan, reflecting a year-on-year growth of 8.10% [2] - The sales gross margin stood at 46.72% [2] Market Position - As of July 31, the company's stock closed at 15.86 yuan, down 2.10%, with a rolling price-to-earnings (PE) ratio of 69.18 times [1] - The average PE ratio for the medical device industry is 54.89 times, with a median of 37.06 times, placing the company at the 92nd position in the industry ranking [1][3] - The total market capitalization of the company is approximately 5.096 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders reached 7,938, an increase of 979 from the previous count [1] - The average market value of shares held by each shareholder is approximately 352,800 yuan, with an average holding of 27,600 shares [1]

Group 1 - The closing price of the company on July 24 was 15.54 yuan, an increase of 2.71%, with a rolling PE ratio of 67.79, marking a new low in 255 days, and a total market value of 4.993 billion yuan [1] - The average PE ratio in the medical device industry is 54.56, with a median of 37.54, placing the company at the 92nd position in the industry ranking [1] - As of the first quarter of 2025, 11 institutions held shares in the company, all being funds, with a total holding of 6.3098 million shares valued at 0.09 billion yuan [1] Group 2 - The main business of the company is the research, production, and sales of blood purification equipment and consumables, along with providing chain blood dialysis medical services [2] - The company's key products include blood perfusion machines, continuous blood purification devices, and various types of dialysis machines and consumables [2] - The company achieved a revenue of 189 million yuan in the first quarter of 2025, representing a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, up 8.10%, with a gross profit margin of 46.72% [2]

Group 1 - The core business of the company is the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [2] - The company has received multiple national and departmental awards for its projects, including the National Science and Technology Progress Award (Second Class) [2] - As of March 31, 2025, the company had a total market capitalization of 4.437 billion yuan and a rolling price-to-earnings (PE) ratio of 60.24, which is higher than the industry average of 51.05 [1][3] Group 2 - The latest quarterly report for Q1 2025 shows the company achieved a revenue of 189 million yuan, representing a year-on-year increase of 16.77%, and a net profit of 37.064 million yuan, with a year-on-year increase of 8.10% [2] - The company's gross profit margin stands at 46.72% [2] - The average PE ratio in the medical device industry is 51.05, with a median of 36.62, positioning the company at the 90th rank within the industry [1][3]

重庆山外山血液净化技术股份有限公司的主营业务是血液净化设备与耗材的研发、生产和销售，并提供 连锁血液透析医疗服务。公司的主要产品是血液灌流机、连续性血液净化设备、血液透析机、血液净化 设备、血液透析浓缩液、血液透析干粉、血液透析器（低通）、血液透析器（高通）、透析液过滤器、 连续性血液净化管路、一次性使用血液灌流器、连锁血液透析中心医疗服务、智慧血透管理。公司项 目"血液净化系统监测与控制系列关键技术及整机设备"荣获国家科学技术进步二等奖，还先后获得国家 信息产业重大技术发明奖、中国电子信息科学技术发明一等奖、中国仪器仪表科学技术一等奖、中国标 准创新贡献奖、中国专利银奖等多项国家和部级奖励，被国家科技部评为国家级创新型企业。 6月23日，山外山今日收盘13.47元，上涨1.28%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到58.76倍，总市值43.28亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.89亿元，同比16.77%；净利润3700.64万元， 同比8.10%，销售毛利率46.72%。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.89倍，行业中值35 ...